US Patent 6,127,425 (Tamoxifen Citrate Oral Solution) Scope, Claims, and Landscape
US 6,127,425 is directed to an oral liquid dosage form of tamoxifen citrate formulated to achieve high concentration while avoiding a complexing agent. The claims lock onto (i) concentration, (ii) the specific solvent system (ethanol + glycol(s) + water, optionally with sweetener), and (iii) two process routes for dissolving or dispersing tamoxifen citrate into that system.
What is the core claim scope?
Independent claim focus (Claim 1)
Claim 1 is the broadest coverage anchor:
- Dosage form: “pharmaceutical preparation” that provides an oral administered dosage form of tamoxifen
- Drug form / salt: tamoxifen citrate
- Concentration: at least 1.5 mg/mL tamoxifen citrate
- Critical formulation condition: “in the absence of a complexing agent”
- Vehicle: “pharmaceutically acceptable solution”
Practical scope read-through
- The patent is not a generic “tamoxifen solution.” It is a tamoxifen citrate oral solution at or above 1.5 mg/mL with a non-complexing-agent solvent approach.
- Oral liquid form is required; routes like injection are outside the claimed dosage form.
Dependent claim escalation (Claims 2-6)
Claims 2 to 6 add strict limitations to the solvent composition and, in later claims, to the glycol identity and water additives.
Claim 2: solvent composition ranges
- Ethanol: 10% to 20% by weight
- Glycol: 10% to 60% by weight
- Water: balances to 100% by volume (with volume percent addition rule stated)
Claim 3: glycol mixture
- Glycol is a mixture of:
- propylene glycol
- glycerol
Claim 4: bulk sweetening agent in water
- Water contains a bulk-sweetening agent
Claim 5: sweetener specification
- Bulk sweetener is sorbitol from 15% to 25% by weight
Claim 6: one concrete “example” composition
- 15% by weight ethanol
- 10% by weight propylene glycol
- 50% by weight glycerol
- 20% by weight of a solution of 70% sorbitol in water
- Plus water as needed to satisfy the 100% volume statement
Claim strategy implication
- The claim set is built with a classic “range-to-specific-formula-to-processed-example” structure.
- The strongest enforceable sweetener formulation is Claim 5/6. The strongest enforceable vehicle breadth is Claim 2, but only within Claim 1’s conditions.
What does the patent cover at the formulation level?
Essential constraints a product must meet to fall into the claim family
A tamoxifen citrate oral solution must satisfy all relevant claim elements:
- Tamoxifen citrate
- Oral dosage form (administered orally)
- Concentration: at least 1.5 mg/mL
- No complexing agent
- Solvent system: at least for dependent coverage, ethanol + glycol + water in specified proportions (and for further dependent coverage, glycol mix identities and sorbitol)
Vehicle architecture
The patent defines a system composed of:
- Ethanol (10%-20% by weight in Claim 2)
- Glycol(s) (10%-60% by weight in Claim 2)
- Water (with explicit volume balancing)
Then it tightens to:
- propylene glycol + glycerol (Claim 3)
- sorbitol in water as bulk sweetener (Claims 4-5)
- A specific quantified solvent blend (Claim 6)
What is the scope of the process claims?
The process claims track the same formulation system, with specific addition/dispersal order.
Claim 7
- Dissolve tamoxifen citrate in the ethanol + glycol components mixture
- Then add the water component and any other additives
Claim 8
- First disperse tamoxifen citrate in the glycol component
- Then add:
- ethanol component
- water component
Claim 9
A more specific step order tied to Claim 3’s glycol mix (propylene glycol + glycerol):
- Disperse tamoxifen citrate in propylene glycol to form a dispersion
- Add the dispersion to glycerol
- Add ethanol
- Add water
Claim 11
- Water component includes additives selected from flavors, sweeteners, coloring agents
- This is tied to the process structure in Claim 9
Process scope implication
- Manufacturing “around” the product claims is sometimes possible if a competitor uses a different order of mixing, but here the order is still tightly prescribed.
- If a competitor uses dissolving vs dispersing, claims 7 vs 8/9 become the discriminators.
How narrow is the “no complexing agent” element?
The key negative limitation is: absence of a complexing agent.
From a claims perspective, this is a hard boundary:
- Any formulation that includes a recognized complexing agent intended to complex tamoxifen may fall outside.
- If a competitor uses other solubilizers or excipients, they still must avoid qualifying as a “complexing agent” under claim interpretation.
The practical risk for generic or reformulation entrants is that many solubilization strategies involve complexation concepts. If that functionality is considered “complexing,” the product may not read onto Claim 1.
Claim-by-claim claim chart (scope map)
| Claim |
What it adds beyond prior claims |
Hard constraints (verbatim scope elements) |
| 1 |
Independent dosage form |
Oral; tamoxifen citrate; at least 1.5 mg/mL; pharmaceutically acceptable solution; no complexing agent |
| 2 |
Vehicle ranges |
Solvent: ethanol 10-20 wt%, glycol 10-60 wt%, water to 100 vol% |
| 3 |
Glycol identity |
Glycol = mixture of propylene glycol + glycerol |
| 4 |
Water additives |
Water contains bulk-sweetening agent |
| 5 |
Sweetener identity |
Sorbitol 15-25 wt% (bulk sweetening agent) |
| 6 |
Concrete quantitative formulation |
15% EtOH wt; 10% PG wt; 50% glycerol wt; 20% of 70% sorbitol solution wt; water to volume basis |
| 7 |
Process route A |
Dissolve tamoxifen citrate in EtOH + glycol mix; then add water/additives |
| 8 |
Process route B |
Disperse in glycol first; then add ethanol; then add water |
| 9 |
Process route C (PG first) |
Disperse in propylene glycol; add to glycerol; add ethanol; add water |
| 10 |
Water additive categories (product) |
Water contains additive(s): flavors, sweeteners, coloring agents |
| 11 |
Water additive categories (process) |
Water component contains flavors, sweeteners, coloring agents |
What is the patent’s likely commercial coverage profile?
Products most exposed
- Oral tamoxifen citrate solutions using ethanol and polyols (especially propylene glycol and glycerol)
- Formulations that deliver >= 1.5 mg/mL
- Products that explicitly avoid complexing agents
- Liquid products using sorbitol as bulk sweetener at 15-25 wt%
- Products matching the specific blend (Claim 6) or close equivalents in the same parameter space
- Products where manufacturing uses one of the claimed addition/dispersal sequences
Products less exposed (by claim element failure)
- Tamoxifen formulations not in citrate salt form
- Oral liquid tamoxifen forms with < 1.5 mg/mL
- Oral solutions using a complexing agent as part of solubilization
- Oral formulations using different solvent systems that do not fall within Claim 2’s ethanol/glycol/water ranges (for dependent claim territory), or that use glycols not comprising propylene glycol + glycerol (for Claim 3+ territory)
- Manufacturing processes that do not follow dissolving/dispersing order restrictions (process claims only)
How does this shape the US patent landscape?
US 6,127,425 reads like a formulation and process patent rather than a new tamoxifen entity. In practical landscape terms, it clusters with other tamoxifen formulation patents that attempt to:
- increase solubility
- stabilize the drug in a liquid vehicle
- enable palatability (sweeteners)
- control manufacturing by stepwise dispersion/dissolution
Landscape “threat model” created by the claim set
- “Solvent recipe” lock-in
- Ethanol and glycol (and particularly propylene glycol + glycerol) are central.
- “No complexing agent” negative limitation
- Pushes future entrants toward non-complexation solubilization strategies.
- “Sweetener in water” lock-in
- Sorbitol 15-25 wt% is a narrow but commercially relevant palatability constraint.
- Manufacturing route claims
- Even if composition matches, process order can matter.
Potential freedom-to-operate outcomes
- If a competitor’s product hits Claim 1 elements and uses similar vehicle chemistry, the matter shifts to whether their system includes a complexing agent and whether it meets the solvent boundaries.
- If the competitor uses sorbitol in the specified range and propylene glycol/glycerol mixture, dependent claims 3-6 become a direct risk surface.
- For process claims, risk is driven by the dispersing/dissolving sequence rather than only final composition.
Key takeaways
- US 6,127,425 protects an oral tamoxifen citrate solution at >= 1.5 mg/mL in the absence of a complexing agent.
- The formulation scope is controlled by a specific solvent system: ethanol (10-20 wt%) + glycol (10-60 wt%) + water to a defined volume basis.
- Claim 3 narrows glycol identity to propylene glycol + glycerol, while Claims 4-6 narrow palatability to sorbitol (15-25 wt%), including a fixed composition blend.
- Process claims cover dissolve-first and disperse-first addition orders, including a propylene glycol dispersion then glycerol then ethanol then water route.
- Landscape-wise, the patent is best positioned as a formulation/process blocking patent for liquid oral tamoxifen citrate recipes that fit its solvent system while avoiding complexing agents.
FAQs
1) Does Claim 1 require sorbitol?
No. Sorbitol appears only in dependent Claims 4-6 as a bulk sweetening agent in the water component.
2) Is propylene glycol mandatory?
Not in Claim 1 or Claim 2. Propylene glycol becomes mandatory in the dependent coverage of Claim 3, which states the glycol component is a mixture of propylene glycol and glycerol.
3) What is the minimum tamoxifen concentration covered?
Claim 1 covers formulations with at least 1.5 mg/mL tamoxifen citrate.
4) Are complexing agents allowed?
Claim 1 requires the formulation to be in the absence of a complexing agent. This is a negative limitation that defines product scope.
5) Do the process claims protect only manufacturing, or also the final product?
The process claims (Claims 7-9, 11) protect specific manufacturing step orders for making the same solution type defined by the formulation claims. Product coverage is governed primarily by Claims 1-6 and 10.
References
[1] US Patent 6,127,425, “Pharmaceutical preparation and process for preparing tamoxifen citrate oral solution,” claims 1-11.
